17193-28-1 Usage
Description
1-Amino-1-cyclopentanecarboxamide is an organic compound that serves as a valuable synthesis intermediate in the development of various pharmaceuticals. It is characterized by its unique molecular structure, which includes an amino group and a cyclopentanecarboxamide group, making it a versatile building block for creating complex molecules with specific biological activities.
Uses
Used in Pharmaceutical Industry:
1-Amino-1-cyclopentanecarboxamide is used as a synthesis intermediate for the development of pharmaceuticals with pharmacological and tumor-inhibiting activities. Its unique molecular structure allows for the creation of amino-cyclopentanecarboxamide derivatives that can potentially target and inhibit the growth of cancer cells, making it a promising candidate for the treatment of various types of cancer.
Additionally, 1-Amino-1-cyclopentanecarboxamide can be utilized in the synthesis of other bioactive molecules with potential applications in the pharmaceutical industry, such as those with anti-inflammatory, analgesic, or anti-microbial properties. Its versatility as a synthesis intermediate makes it a valuable asset in the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 17193-28-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,1,9 and 3 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 17193-28:
(7*1)+(6*7)+(5*1)+(4*9)+(3*3)+(2*2)+(1*8)=111
111 % 10 = 1
So 17193-28-1 is a valid CAS Registry Number.
InChI:InChI=1/C6H12N2O/c7-5(9)6(8)3-1-2-4-6/h1-4,8H2,(H2,7,9)
17193-28-1Relevant articles and documents
Original loading and Suzuki conditions for the solid-phase synthesis of biphenyltetrazoles. Application to the first solid-phase synthesis of irbesartan
Cousaert, Nicolas,Willand, Nicolas,Gesquière, Jean-Claude,Tartar, André,Déprez, Beno?t,Deprez-Poulain, Rebecca
, p. 2743 - 2747 (2008/09/18)
Biphenyltetrazoles are recognized privileged structures. Among them, the therapeutically important class of sartans displays antagonistic activity on AT1 receptors. We have developed a method for anchoring tetrazole derivatives via the heterocycle on a hydroxylated resin using zinc triflate. New Suzuki-Miyaura cross-coupling conditions are developed for the quantitative formation of the phenyl-phenyl bond. Our straightforward synthesis scheme, starting from the conserved phenyltetrazole moiety and ending with the appending of the structurally variable moiety, is well suited to the preparation of sartans and their analogues at a laboratory scale. We thus describe here the first solid phase synthesis of irbesartan, a marketed AT1 antagonist.
Form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
-
Page column 7, (2010/02/08)
The invention relates to a novel crystalline form of irbesartan, to pharmaceutical compositions containing it, to processes for preparing it, and to a method for treating cardiovascular diseases utilizing it.
Polypeptides. VII. Variations of the phenylalanyl position in the C-terminal tetrapeptide amide sequence of the gastrins.
Gregory,Jones,Morley
, p. 531 - 540 (2007/10/06)
-